International Marketing Manager, Immunology, Spondylarthritis
Illinois, USA (On-site)
Salary Not AvailableMid Level3+ years expFull time
Posted 3 days ago
Job Summary
Original Job Description
AbbVie
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
Marketing team
3,267
Employees
60K
Headquarters
North Chicago, Illinois, USA
Founded
2013
Employee Sentiment
Overall Rating
4 / 5
Based on 5,754 reviews
Recommend to a Friend
78%
CEO Approval
88%
Source: Glassdoor
Traffic Signals
Monthly Visitors
1.4M
Monthly Google Ads Budget
$37.3K
Traffic Source Mix
Search
35%
Direct
45.7%
Referral
11.2%
Social
6.1%
Paid
1.8%
Headcount Trend
Current headcount: ~59.9K
Funding
Total Funding
$23.0B
Last Raise
18 days ago
Last Raise Amount
$8.0B
- 2026-02-26Post IPO Debt • $8.0B
- 2024-02-27Post IPO Debt • $15.0B
- 2023-03-08Post IPO Equity • $250.0K
Recent News
Fierce Biotech
UPDATED: AbbVie to end Calico collab after 11-year run, plans layoffs: Stat
Nov 13, 2025
BioSpace
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+
Nov 13, 2025
statnews.com
AbbVie cuts ties with Google-backed longevity company, lays off scientists
Nov 12, 2025
Yahoo Finance
Jim Cramer Says “I Found the AbbVie Call Particularly Jarring”
Nov 5, 2025
Yahoo Finance
Analyst on AbbVie (ABBV): ‘Stay Long’
Nov 3, 2025
The Motley Fool
Why AbbVie Stock Flopped on Friday
Nov 1, 2025
Barron's
AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.
Oct 31, 2025
Fierce Pharma
AbbVie boosts revenue forecast by $400M thanks to booming sales of Skyrizi, Rinvoq
Oct 31, 2025
Yahoo Finance
AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira ...
Oct 31, 2025
Yahoo Finance
How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts
Oct 25, 2025
Yahoo Finance
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
Oct 24, 2025
Reuters
AbbVie's Rinvoq shows superiority over Humira in head-to-head arthritis study
Oct 20, 2025
PR Newswire
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
Oct 13, 2025
Fortune
How pharma giant AbbVie holds leaders accountable for culture
Oct 9, 2025
The Motley Fool
Why AbbVie Stock Soared in September
Oct 8, 2025
Yahoo Finance
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
Oct 6, 2025
Pharmaceutical Technology
AbbVie breaks ground on $70m US biologics site amid Trump pressure
Oct 1, 2025
The Motley Fool
Why AbbVie Stock Cruised to an Almost 6% Gain Today
Oct 1, 2025
Fierce Pharma
AbbVie charts next leg of US investment journey with $70M expansion in MA
Oct 1, 2025
Reuters
AbbVie to launch ovarian cancer drug in UK at US price
Sep 29, 2025
PR Newswire
REGENXBIO Announces Presentation at the World Muscle Society
Sep 29, 2025
PR Newswire
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
Sep 29, 2025
EIN Presswire
United States Cancer Therapeutics Market to Hit $491.6 Billion by 2032, Driven by Precision and Immunotherapy Advances
Sep 29, 2025
BioSpace
September’s FDA Action Bolsters Keytruda, Ultra-Rare Disease but Deals Two SMA Defeats
Sep 29, 2025
BioSpace
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson’s Disease
Sep 29, 2025
MarketScreener
AbbVie to launch ovarian cancer drug in UK at the same list price as US
Sep 29, 2025
PR Newswire
Mosaic Consulting Expands Salesforce and Braze Services, Showcases Software Expertise with DrugAlert.ai
Sep 29, 2025
PR Newswire
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
Sep 29, 2025
Investing.com
AbbVie to launch ovarian cancer drug in UK at US price
Sep 29, 2025
MarketScreener
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
Sep 29, 2025
American Hospital Association
District court denies preliminary injunctions by drug companies in challenges to Maine’s 340B contract pharmacy law
Sep 24, 2025
BioSpace
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
Sep 24, 2025
Livemint.com
Glenmark inks $18 million deal for cancer drug with China’s Hengrui
Sep 24, 2025
Benzinga.com
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies
Sep 24, 2025
AbbVie
Care and Commitment: Celebrating AbbVie's 2025 Working Parents/Caregivers
Sep 23, 2025
The Real Deal
Vernon Hills office hits market as landlord scrambles to cover loan
Sep 23, 2025
MarketScreener
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Sep 23, 2025
PR Newswire
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
Sep 23, 2025
MarketScreener
Allergan Aesthetics, an AbbVie company Announces Expansion of SKINVIVE by JUVEDERM into 35 New Markets
Sep 23, 2025
Amneal Pharmaceuticals LLC
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Sep 23, 2025
MarketScreener
AbbVie to Launch Skinvive in 35 Additional Markets
Sep 23, 2025
Orange County Business Journal
Allergan Aesthetics to Launch Skinvive in 35 New Markets
Sep 23, 2025
BioSpace
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 22, 2025
PR Newswire
Parkinson's Disease Therapeutics Market Size to Hit US$ 12.83 Billion by 2033, Report by DataM Intelligence
Sep 22, 2025
The Motley Fool
1 Top Dividend Stock to Buy and Hold Forever
Sep 22, 2025
The Motley Fool
What Is One of the Best Pharmaceutical Stocks to Buy Right Now?
Sep 22, 2025
BioSpace
Psychedelics Space Enters New Era as AbbVie Dives In
Sep 22, 2025
Morningstar.com
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 19, 2025
MarketScreener
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 19, 2025
Yahoo Finance
BMO Lifts AbbVie Inc. (ABBV) Price Target to $240 After Rinvoq Litigation Win
Sep 18, 2025
BioSpace
Roche Makes Major MASH Move With $3.5B 89bio Buy
Sep 18, 2025
thefly.com
AbbVie just upgraded at Berenberg, here's why
Sep 17, 2025
Benzinga.com
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Sep 17, 2025
Reuters
Berenberg sees opportunity for pharma cos despite policy risks; upgrades Novo
Sep 17, 2025
thefly.com
AbbVie price target raised by $35 at JPMorgan, here's why
Sep 16, 2025
Law360
AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037
Sep 16, 2025
FierceBiotech
Novo amylin drug underperforms Wegovy in efficacy, but scores in tolerability
Sep 16, 2025
FierceBiotech
Genmab discards clinical ADC picked up in last year's $1.8B ProfoundBio buy
Sep 16, 2025
Morningstar.com
Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
Sep 16, 2025
FiercePharma
FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters
Sep 16, 2025
EIN Presswire
Maricel Torrent Recognized by Influential Women 2025
Sep 15, 2025
Venture Capital Firms
Saisei Ventures Appoints James Feliciano as Venture Partner
Sep 15, 2025
Oncology Pipeline
AbbVie broadens its telisotuzumab conjugate push | ApexOnco - Clinical Trials news and analysis
Sep 12, 2025
BioSpace
AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement
Sep 12, 2025
Morningstar.com
Dow Jones Top Company Headlines at 9 PM ET: Microsoft, OpenAI Truce Clears Hurdle in Path to For-Profit Conversion | Adobe ...
Sep 12, 2025
thefly.com
Wells sees AbbVie Rinvoq settlement being worth $11-$24 per share
Sep 11, 2025
thefly.com
AbbVie price target raised by $25 at BMO Capital, here's why
Sep 11, 2025
Morningstar.com
AbbVie in Settlement With Generic Drugmakers on Rinvoq
Sep 11, 2025
MarketScreener
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
Sep 11, 2025
Yahoo Finance - Business Finance, Stock Market, Quotes, News
AbbVie stock rises after securing patent protection for RINVOQ until 2037
Sep 11, 2025
Morningstar.com
Dow Jones Top Company Headlines at 3 PM ET: Paramount Skydance Prepares Ellison-Backed Bid for Warner Bros. Discovery | AbbVie ...
Sep 11, 2025
Morningstar.com
AbbVie On Pace For Record High Close — Data Talk
Sep 11, 2025
thefly.com
AbbVie jumps 4% to $220.77 after settling with Rinvoq generic makers
Sep 11, 2025
Dow Jones Newswires
Dow Jones Top Company Headlines at 3 PM ET: Paramount Skydance Prepares Ellison-Backed Bid for Warner Bros. Discovery | AbbVie ...
Sep 11, 2025
Business Standard India
Glenmark gains 3% on $700 mn upfront payment from AbbVie licensing deal
Sep 9, 2025
PR Newswire
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
Sep 9, 2025
Business Standard India
Glenmark Pharma shares rise as arm receives an upfront payment of $700 mn
Sep 9, 2025
MarketScreener
Transcript : AbbVie Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 10
Sep 9, 2025
Hindu Business Line
Glenmark Pharma subsidiary IGI gets $700 million upfront payment from AbbVie
Sep 9, 2025
The Motley Fool
1 Reason Every Investor Should Know About AbbVie (ABBV)
Sep 8, 2025
PharmiWeb
"Anti-Parkinson's Drugs: Global Markets to 2030"
Sep 8, 2025
Boston Herald
Trump’s factory boom stalled for now as payrolls keep shrinking
Sep 6, 2025
PR Newswire
Run. Rally. Rise. The 2025 Race to End Women's Cancer is Back in Washington, D.C.
Sep 5, 2025
Clinical Trials Arena
AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial
Sep 4, 2025
Business Standard India
Don't miss out on these 2 stocks, say analysts at MOFSL; details inside
Sep 4, 2025
BioSpace
After 2021 SPAC Bubble, How Did These 6 Biotechs Fare?
Sep 3, 2025
MarketScreener
Antitrust Softens, Yields Still Rise
Sep 3, 2025
thefly.com
AbbVie reports results from Phase 2 EPCORE NHL-6 trial
Sep 3, 2025
PharmiWeb
Genmab Announces Updated Results from Phase 2 EPCORE® NHL...
Sep 3, 2025
MarketScreener
Global drugmakers rush to boost US presence as tariff threat looms
Sep 3, 2025
PR Newswire
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
Sep 3, 2025
Precedence Research
Multiple Myeloma Market Size Projected USD 49.89 Billion by 2034
Sep 3, 2025
MarketScreener
AbbVie Gets Health Canada Approval for Ovarian-Cancer Treatment
Sep 2, 2025
Canada NewsWire
Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers Français
Sep 2, 2025
MarketScreener
AbbVie Says Health Canada Approves Elahere in Some Types of Ovarian Cancers
Sep 2, 2025
prnasia.com
AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work
Sep 1, 2025
EIN Presswire
JLS Fund Congratulates Largest Portfolio Holding, Gilamesh Pharmaceuticals on $1.2 Billion Deal with AbbVie (NYSE: ABBV)
Sep 1, 2025
Labiotech.eu
Blood Cancer Awareness Month: What biotech holds in store
Sep 1, 2025
The Motley Fool
5 High-Yield Dividend Stocks I Plan on Holding for the Next 10 Years or Longer
Aug 31, 2025
Zawya.com
Great Place to Work Middle East announces the 2025 Best Workplaces in Asia
Aug 30, 2025